Blood Transfusion最新文献

{"title":"Histocompatibility assessment in hematopoietic stem cell transplantation: recommendations from the Italian Society for Immunogenetics and Transplantation Biology (Associazione Italiana di Immunogenetica e Biologia dei Trapianti - AIBT).","authors":"Roberto Crocchiolo, Caterina Fusco, Marco Andreani, Giovanni Rombolà, Michela Falco, Cinzia Vecchiato, Lucia Garbarino, Lia Mele, Allegra B Mazzi, Alessandra Picardi, Letizia Lombardini, Simona Pollichieni, Maria C De Stefano, Fabio Ciceri, Massimo Cardillo, Franco Papola","doi":"10.2450/BloodTransfus.495","DOIUrl":"10.2450/BloodTransfus.495","url":null,"abstract":"<p><p>The outcome of allogeneic hematopoietic stem cell transplantation (HSCT) is significantly influenced by the degree of HLA histocompatibility between donor and recipient. To provide shared indications for required histocompatibility testing and interpretation before HSCT, the Italian Society for Immunogenetics and Transplantation Biology (Associazione Italiana di Immunogenetica e Biologia dei Trapianti [AIBT]) gathered members and created a working group to discuss and develop recommendations for histocompatibility assessment in HSCT.After a review of the literature and multiple panel discussions, AIBT developed up-to-date recommendations for the resolution levels of HLA typing, histocompatibility definitions of patients and donors, importance of anti-HLA antibodies, and significance of NK alloreactivity, which are reported in this document. These recommendations have been shared with the Italian Group for Bone Marrow Transplantation (Gruppo Italiano per il Trapianto di Midollo Osseo, cellule staminali emopoietiche e terapia cellulare [GITMO]) and the Italian National Center for Transplantation (Centro Nazionale Trapianti [CNT]). Notably, the increased use of HLA-mismatched transplantation (i.e., mismatched unrelated, haploidentical) in recent years has made these indications even more relevant for the standardization and improvement of quality of care.This document represents a useful instrument for health care workers involved in the field of HSCT, enhancing synergy with transplant physicians and enabling greater optimization of the available resources.</p>","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":"338-349"},"PeriodicalIF":2.4,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251828/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10185300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A voluntary transfusion recipient registry in Korea as a database for blood group antibodies.","authors":"Dong Woo Shin, Yun Ji Hong, Jungwon Hyun, Eun Young Song, Kyoung Un Park","doi":"10.2450/BloodTransfus.429","DOIUrl":"10.2450/BloodTransfus.429","url":null,"abstract":"<p><strong>Background: </strong>Several types of transfusion-related registries have been developed to improve patient outcomes and blood banks. In Korea, a transfusion program functioning as a blood group antibody database and a reference laboratory has been in operation since July 2013. This study was conducted to determine the current status of blood group antigens and antibodies in Korea and propose a model for registries in the field of transfusion medicine.</p><p><strong>Materials and methods: </strong>Cases with unexpected red cell antibodies were registered online in the voluntary transfusion registry. Specific antigen-negative frequencies were calculated based on the recorded data. To determine the frequencies of RhCE antigens, data added via the Blood Information Sharing System were also analyzed. Data added to the registries between July 2013 and June 2022 were included in the analysis.</p><p><strong>Results: </strong>Among 9,048 antibody cases registered from 29 hospitals, anti-E alone was identified most commonly, followed by anti-E and c, anti-C and e, anti-Lea, and anti-M (2,202, 1,792, 757, 618, and 383 cases, respectively). The frequencies of E-, E-c-, C-e-, Le(a-), and M- were 49.1%, 41.6%, 9.1%, 69.4%, and 21.8%, respectively.</p><p><strong>Discussion: </strong>The distributions of antibodies and antigen frequencies were estimated through the transfusion registry. Antigen frequencies were calculated based on the results of antigen typing of red blood cell components performed at the time of issuing. The online transfusion registry serving as a blood group antibody database is useful for determining the frequencies of blood group antigens and antibodies.</p>","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":"283-291"},"PeriodicalIF":2.4,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10185298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A potential food-related acute allergic transfusion reaction.","authors":"Kelly Johnson-Arbor, Colleen Gilstad, Richard Verstraete","doi":"10.2450/BloodTransfus.677","DOIUrl":"10.2450/BloodTransfus.677","url":null,"abstract":"","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":"367-368"},"PeriodicalIF":2.4,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138812031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"No evidence for liberal transfusion in acute myocardial infarction.","authors":"Aryeh Shander, Kevin M Trentino, Caroline Evans, John G F Cleland","doi":"10.2450/BloodTransfus.819","DOIUrl":"10.2450/BloodTransfus.819","url":null,"abstract":"","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":"312-315"},"PeriodicalIF":2.4,"publicationDate":"2024-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141471939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe breakthrough hemolysis during compassionate use of Pegcetacoplan in paroxysmal nocturnal hemoglobinuria: managing an emergency.","authors":"Elisabetta Metafuni, Antonella Carbone, Luca Petriccione, Sabrina Giammarco, Maria A Limongiello, Silvia Bellesi, Patrizia Chiusolo, Simona Sica","doi":"10.2450/BloodTransfus.639","DOIUrl":"10.2450/BloodTransfus.639","url":null,"abstract":"","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":"360-362"},"PeriodicalIF":2.4,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251835/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141471941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients.","authors":"Arianna Zappaterra, Ivan Civettini, Anna Maria Cafro, Laura Pezzetti, Silvia Pierini, Michela Anghilieri, Laura Bellio, Paola Bertazzoni, Giovanni Grillo, Periana Minga, Maria L Pioltelli, Emanuele Ravano, Marianna Sassone, Clara V Viganò, Elisabetta B Volpato, Carlo Gambacorti-Passerini, Silvano Rossini, Roberto Cairoli, Roberto Crocchiolo","doi":"10.2450/BloodTransfus.667","DOIUrl":"10.2450/BloodTransfus.667","url":null,"abstract":"<p><strong>Background: </strong>Induction with daratumumab-based regimens followed by autologous stem cell transplantation is the current standard for newly diagnosed multiple myeloma (NDMM) patients eligible for intensive chemotherapy. However, concerns emerged regarding potential negative effects following daratumumab-based treatment on CD34+ mobilization. We here compared CD34+ mobilization and clonogenic potential between daratumumab and non-daratumumab based therapy without upfront plerixafor administration among patients affected by NDMM.</p><p><strong>Materials and methods: </strong>Clinical, mobilization and clonogenic data from 41 consecutively enrolled NDMM patients were analyzed. Patients underwent collection of autologous CD34+ by apheresis at the ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, from January 2021 to March 2023. Clonogenicity analysis was performed on BFU-E and CFU-GM.</p><p><strong>Results: </strong>Seventy-five percent of daratumumab-treated patients underwent >1 apheresis, compared to 24% of non-daratumumab patients (p=0.0017). Daratumumab-treated patients had significantly lower CD34+ count (mean 38 vs 79/μL, respectively; p=0.0011), with a median CD34+ harvest of 3.98×10⁶/kg (range 1.68-9.18) vs 6.87×10⁶/kg (range 1.63-16.85) in non-daratumumab-treated (p=0.0006). In multivariate analysis the likelihood of undergoing >1 apheresis was significantly higher in older patients (OR 1.2, 95% CI 1-1.4, Z=2.10, p=0.03) and daratumumab-treated patients (OR 15, 95% CI 2.8-129, p=0.004). Moreover, daratumumab-based induction therapy demonstrated an independent negative association with BFU-E colony formation (p=0.0148), even when accounting for patient age and CD34+ levels.</p><p><strong>Discussion: </strong>Our findings underscore the impact of daratumumab-based treatment on CD34+ mobilization in a real-life, upfront plerixafor-free population of NDMM patients. Higher probability of requiring multiple apheresis occurred among daratumumab-treated patients. Interestingly, the observation that daratumumab might negatively impact BFU-E colony formation, independent of CD34+ cell count, offers novel biological perspectives. Appropriate strategies should be adopted by the Apheresis teams to mitigate these potential negative effects.</p>","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":"328-337"},"PeriodicalIF":2.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251823/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139693361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights and innovations in Blood Transfusion.","authors":"Serelina Coluzzi, Luca Mascaretti","doi":"10.2450/BloodTransfus.845","DOIUrl":"10.2450/BloodTransfus.845","url":null,"abstract":"","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":"22 4","pages":"277-278"},"PeriodicalIF":2.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251831/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141724883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights and innovations in Blood Transfusion.","authors":"Serelina Coluzzi, Luca Mascaretti","doi":"10.2450/BloodTransfus.845","DOIUrl":"10.2450/BloodTransfus.845","url":null,"abstract":"","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":"22 4","pages":"277-278"},"PeriodicalIF":2.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251831/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of erythropoietin to prevent red blood cell transfusion in a 2018-2020 two-center cohort of preterm infants.","authors":"Noémie Bailly, Roselyne Brat, Geraldine Favrais","doi":"10.2450/BloodTransfus.641","DOIUrl":"10.2450/BloodTransfus.641","url":null,"abstract":"<p><strong>Background: </strong>Treatment with recombinant human erythropoietin (rHu-EPO) modestly prevented packed red blood cell transfusions (pRBCTs) in preterm infants in studies performed several years ago. In France, some neonatal units stopped using rHu-EPO, while others continued. The aim of this study was to explore the role of rHu-EPO in the prevention of pRBCTs in a recent cohort of preterm infants.</p><p><strong>Materials and methods: </strong>Preterm infants who met rHu-EPO indications and were hospitalised between 2018 and 2020 in two neonatal units -one that did not use rHu-EPO and another that did- were eligible. Data about the neonatal history, rHu-EPO and iron treatments and pRBCT indications and volumes were collected. Infants exposed and not exposed to rHu-EPO were compared in univariate and multivariate analyses using backward logistic regression and Cox proportional hazards regression.</p><p><strong>Results: </strong>A total of 257 patients exposed to rHu-EPO and 285 patients who were not exposed were included. Three profiles emerged. In the infants with a gestational age <28 weeks, the cumulative pRBCT volume/kg was similar regardless of rHu-EPO exposure (mean difference -2.8 mL, 95% confidence interval -16.1, 10.5, p=0.68). In the infants born between 28 and 30 weeks, a late pRBCT was prevented in the rHu-EPO group (single pRBCT: no rHu-EPO 22.1% vs rHu-EPO 8%, p=0.003). However, rHu-EPO was not independently associated with avoidance of this pRBCT. Finally, the need for pRBCT was low in the infants born after 30 weeks of gestation, making rHu-EPO treatment futile. In contrast, early iron supplementation was revealed to be critical in preventing pRBCT.</p><p><strong>Discussion: </strong>No benefit of rHu-EPO in preventing pRBCT was observed in our cohort. The place of rHu-EPO in future requires careful consideration of the population concerned, adjustment of the therapeutic schedule and evolution of the indications for pRBCT.</p>","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":"303-311"},"PeriodicalIF":2.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251825/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139693294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"45° Convegno Nazionale di Studi di Medicina Trasfusionale, Rimini, 29-31 maggio 2024.","authors":"Francesco Fiorin, Patrizia Di Gregorio, Pierluigi Berti, Antonella Matteocci, Giorgio Gandini, Serelina Coluzzi, Renato Messina, Silvano Rossini, Gianluca Ubezio, Domenico Visceglie, Giuseppe Aprili","doi":"10.2450/BloodTransfus.2024.Suppl1","DOIUrl":"https://doi.org/10.2450/BloodTransfus.2024.Suppl1","url":null,"abstract":"","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141181421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}